MX2015014773A - Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja. - Google Patents

Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja.

Info

Publication number
MX2015014773A
MX2015014773A MX2015014773A MX2015014773A MX2015014773A MX 2015014773 A MX2015014773 A MX 2015014773A MX 2015014773 A MX2015014773 A MX 2015014773A MX 2015014773 A MX2015014773 A MX 2015014773A MX 2015014773 A MX2015014773 A MX 2015014773A
Authority
MX
Mexico
Prior art keywords
egfr antibodies
cancer treatments
low fucosylation
cancer
antibodies
Prior art date
Application number
MX2015014773A
Other languages
English (en)
Spanish (es)
Inventor
Steffen Goletz
Antje Danielczyk
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of MX2015014773A publication Critical patent/MX2015014773A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2015014773A 2013-04-22 2014-04-22 Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja. MX2015014773A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13002106 2013-04-22
EP13002108 2013-04-22
PCT/EP2014/058118 WO2014173886A1 (en) 2013-04-22 2014-04-22 Anti-cancer treatments with anti-egfr antibodies having a low fucosylation

Publications (1)

Publication Number Publication Date
MX2015014773A true MX2015014773A (es) 2016-03-04

Family

ID=50729450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014773A MX2015014773A (es) 2013-04-22 2014-04-22 Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja.

Country Status (13)

Country Link
US (1) US20160068609A1 (https=)
EP (1) EP2989126A1 (https=)
JP (1) JP2016516800A (https=)
KR (1) KR20150144804A (https=)
CN (1) CN105229030A (https=)
AU (1) AU2014257650A1 (https=)
BR (1) BR112015025955A2 (https=)
CA (1) CA2908819A1 (https=)
EA (1) EA201591977A1 (https=)
MX (1) MX2015014773A (https=)
SG (1) SG11201507743XA (https=)
WO (1) WO2014173886A1 (https=)
ZA (1) ZA201507246B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
CN105820248A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型抗egfr单克隆抗体的制备方法及应用
CN105399830B (zh) * 2015-09-08 2019-11-19 北京天广实生物技术股份有限公司 抗egfr人源化单克隆抗体、其制备方法及用途
US20170247458A1 (en) * 2016-01-10 2017-08-31 Sorrento Therapeutics, Inc. Safety for Treating Cancers with a Glycosylated Chimeric Antibody to EGFR
SI3449939T1 (sl) 2016-04-27 2022-06-30 Green Cross Corporation Farmacevtski sestavek za zaviranje metastaz pri raku, ki kot učinkovino obsega protitelo, ki se specifično veže na receptor za epidermalni rastni faktor
US11649291B2 (en) 2016-05-24 2023-05-16 Insmed Incorporated Antibodies and methods of making same
WO2018013673A1 (en) * 2016-07-13 2018-01-18 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
KR101884614B1 (ko) 2016-10-11 2018-08-02 신일제약주식회사 Fab 단편 및 이의 용도
CN111315776A (zh) * 2017-03-29 2020-06-19 葛莱高托普有限公司 Pd-l1和ta-muc1抗体
CN118267470A (zh) * 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
KR20200031571A (ko) * 2017-05-29 2020-03-24 가마맵스 파마 암 연관 면역억제의 억제제
US20210269530A1 (en) * 2018-05-14 2021-09-02 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
JP7493237B2 (ja) * 2018-11-14 2024-05-31 学校法人金沢医科大学 びまん性胃がんを治療するための医薬組成物
CN112300278A (zh) * 2019-07-25 2021-02-02 上海交通大学 抗人egfr嵌合抗体及其制备方法和用途
MX2022013182A (es) * 2020-04-24 2023-01-16 Merus Nv Tratamiento de cánceres con un anticuerpo que se une a lgr5 y egfr.
CN115960214A (zh) * 2021-10-12 2023-04-14 中国科学院分子细胞科学卓越创新中心 中和呼吸道合胞病毒的全人抗体的设计及应用
EP4476263A4 (en) * 2022-02-09 2026-01-28 Dragonfly Therapeutics Inc PHARMACEUTICAL FORMULATIONS AND THERAPEUTIC USES OF MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO EGFR, NKG2D AND CD16

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
AU2006211037B2 (en) * 2005-02-07 2012-05-24 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
SI2073842T1 (sl) 2006-09-10 2015-05-29 Glycotope Gmbh Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles
US20110200595A1 (en) * 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2012020065A1 (en) * 2010-08-10 2012-02-16 Glycotope Gmbh Fab-glycosylated antibodies
EP2603527A1 (en) * 2010-08-10 2013-06-19 Glycotope GmbH Humanized egfr antibodies

Also Published As

Publication number Publication date
CA2908819A1 (en) 2014-10-30
SG11201507743XA (en) 2015-11-27
JP2016516800A (ja) 2016-06-09
EA201591977A1 (ru) 2016-06-30
KR20150144804A (ko) 2015-12-28
US20160068609A1 (en) 2016-03-10
BR112015025955A2 (pt) 2017-10-17
CN105229030A (zh) 2016-01-06
ZA201507246B (en) 2016-12-21
WO2014173886A1 (en) 2014-10-30
EP2989126A1 (en) 2016-03-02
AU2014257650A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
MX2015014773A (es) Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja.
MX2015014500A (es) Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9.
PT2958945T (pt) Terapia de combinação envolvendo anticorpos contra claudina 18.2 para tratamento de cancro
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
WO2015009726A3 (en) Medical uses of cd38 agonists
PH12016500839A1 (en) Combination theraphy of an anti cd20 antibody with a btk inhibitor
EA201890411A1 (ru) Терапевтически активные соединения и способы их применения
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
NZ719049A (en) Cancer treatment with combination of plinabulin and taxane
HK1221174A1 (zh) 用於治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法
HK1221424A1 (zh) 治疗癌症的药物组合
GEAP202114756A (en) Combination therapy for the treatment of cancer
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
HK1221150A1 (zh) 用二氢吡嗪并-吡嗪类对癌症的治疗
EP3019138A4 (en) Guiding means for administering acupuncture and other healing procedures
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
HK1214752A1 (zh) 由产甲烷菌引起或与之相关的疾病及病状的诊断、选择及治疗方法
MX2016007445A (es) Inhibidores de f1f0-atpasa de trifluorometil pirazolil guanidina y usos terapeuticos de los mismos.
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
ZA201708686B (en) Nanoparticles for use as a therapeutic vaccine
NZ701974A (en) Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation
SMT202200458T1 (it) Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
PL2976360T3 (pl) Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego
EA201690445A1 (ru) Лечение рака
HK1220133A1 (zh) 改善微血管完整性的方法